NZ584998A - Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor - Google Patents

Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Info

Publication number
NZ584998A
NZ584998A NZ584998A NZ58499808A NZ584998A NZ 584998 A NZ584998 A NZ 584998A NZ 584998 A NZ584998 A NZ 584998A NZ 58499808 A NZ58499808 A NZ 58499808A NZ 584998 A NZ584998 A NZ 584998A
Authority
NZ
New Zealand
Prior art keywords
methanone
yloxy
pyridin
furan
tetrahydro
Prior art date
Application number
NZ584998A
Other languages
English (en)
Inventor
Michael A Letavic
Emily M Stocking
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ584998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ584998A publication Critical patent/NZ584998A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ584998A 2007-11-20 2008-11-17 Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor NZ584998A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98924607P 2007-11-20 2007-11-20
PCT/US2008/083764 WO2009067401A1 (en) 2007-11-20 2008-11-17 Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor

Publications (1)

Publication Number Publication Date
NZ584998A true NZ584998A (en) 2012-08-31

Family

ID=40297867

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584998A NZ584998A (en) 2007-11-20 2008-11-17 Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Country Status (22)

Country Link
US (1) US8883776B2 (enExample)
EP (1) EP2222664B1 (enExample)
JP (1) JP5498390B2 (enExample)
KR (1) KR101546712B1 (enExample)
CN (2) CN101868454A (enExample)
AR (2) AR069387A1 (enExample)
AU (1) AU2008326561B2 (enExample)
BR (1) BRPI0820481A2 (enExample)
CA (1) CA2706328C (enExample)
CL (1) CL2008003465A1 (enExample)
CO (1) CO6210700A2 (enExample)
CR (1) CR11529A (enExample)
EA (1) EA018582B1 (enExample)
EC (1) ECSP10010190A (enExample)
MX (1) MX2010005488A (enExample)
MY (1) MY158253A (enExample)
NI (1) NI201000086A (enExample)
NZ (1) NZ584998A (enExample)
TW (1) TWI491604B (enExample)
UA (1) UA103468C2 (enExample)
WO (1) WO2009067401A1 (enExample)
ZA (1) ZA201004334B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US20090170869A1 (en) * 2007-09-06 2009-07-02 Desmond John Best Piperazine derivative having affinity for the histamine h3 receptor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
BRPI0913057A2 (pt) * 2008-05-08 2015-10-13 Evotec Ag azetidinas e ciclobutanos como antagonistas de receptor de histamina h3
HUE044837T2 (hu) 2009-03-18 2019-11-28 Janssen Pharmaceutica Nv Eljárás hisztamin H3 receptor modulátorok elõállítására
EP2482657A4 (en) * 2009-09-21 2013-05-15 Univ Vanderbilt O-BENZYL-NICOTINAMIDANALOGA AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS
CN103826616B (zh) 2011-07-07 2016-08-10 爱尔兰詹森科学公司 地瑞纳韦组合配制品

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (de) 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden
BE726551A (enExample) 1968-01-22 1969-06-16
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
DE3366369D1 (en) 1982-03-17 1986-10-30 Smith Kline French Lab Pyridine derivatives
GB8311443D0 (en) 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
GB8320505D0 (en) 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
GB8332091D0 (en) 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
JPS61149119A (ja) 1984-12-22 1986-07-07 旭光学工業株式会社 検眼用試験枠
US4792547A (en) 1985-12-26 1988-12-20 Hokuriku Pharmaceutical Co., Ltd. Pyrazine-2-carboxamide derivatives useful in treating allergic disease
JPH0637595B2 (ja) 1986-08-06 1994-05-18 日本ペイント株式会社 陰極電着塗料組成物
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3354271B2 (ja) 1993-02-25 2002-12-09 三共株式会社 ピリジルオキシアミド誘導体
DE69628705T2 (de) 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
DE69627709T2 (de) 1995-12-28 2004-02-26 Kureha Kagaku Kogyo K.K. N-(unsubstituierte oder substituierte)-4-substituierte-6-(unsubstituierte oder substituierte)phenoxy-2-pyridincarboxamide oder -thiocarboxamide, verfahren zu deren herstellung sowie herbizide
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
CZ20013000A3 (cs) 1999-02-26 2002-02-13 Merck & Co., Inc. Nové sulfonamidové sloučeniny a jejich pouľití
EA005820B1 (ru) 1999-05-21 2005-06-30 Биовитрум Аб Агонисты и антагонисты рецепторов 5-ht
US6399607B1 (en) 1999-07-02 2002-06-04 Research Foundation-State University Of New York Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002322163A (ja) 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
JP2005505506A (ja) * 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
US7196080B2 (en) 2001-06-15 2007-03-27 Astellas Pharma Inc. Phenylpyridinecarbonylpiperazinederivative
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
JP2005507423A (ja) 2001-11-01 2005-03-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲン合成酵素キナーゼ３ベータ阻害剤（ｇｓｋ３阻害剤）としてのヘテロアリールアミン
PL372390A1 (en) 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037800A1 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
WO2004037801A1 (en) 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CN1812981A (zh) 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
WO2005023247A1 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CA2561945A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
EP1761496A2 (en) 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1948607B1 (en) 2005-09-16 2010-04-07 Janssen Pharmaceutica, N.V. Cyclopropyl amines as modulators of the histamine h3 receptor
EP1966143A2 (en) 2005-12-21 2008-09-10 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
EP1976848A2 (en) 2005-12-21 2008-10-08 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
MY146506A (en) 2006-05-30 2012-08-15 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
JP2009542706A (ja) 2006-06-29 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体の置換ベンズアミドモジュレーター
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
TW200936579A (en) 2009-09-01
KR20100098636A (ko) 2010-09-08
US8883776B2 (en) 2014-11-11
HK1147994A1 (en) 2011-08-26
CA2706328A1 (en) 2009-05-28
CL2008003465A1 (es) 2009-03-06
ZA201004334B (en) 2011-10-26
AU2008326561B2 (en) 2013-12-05
ECSP10010190A (es) 2010-06-29
JP2011503233A (ja) 2011-01-27
AR110977A2 (es) 2019-05-22
CN101868454A (zh) 2010-10-20
AR069387A1 (es) 2010-01-20
BRPI0820481A2 (pt) 2015-06-16
CN105712977A (zh) 2016-06-29
AU2008326561A1 (en) 2009-05-28
US20090131415A1 (en) 2009-05-21
MY158253A (en) 2016-09-30
CA2706328C (en) 2016-04-19
JP5498390B2 (ja) 2014-05-21
CN105712977B (zh) 2021-06-29
CR11529A (es) 2012-10-25
WO2009067401A1 (en) 2009-05-28
KR101546712B1 (ko) 2015-08-24
EA018582B1 (ru) 2013-09-30
UA103468C2 (ru) 2013-10-25
TWI491604B (zh) 2015-07-11
EA201070637A1 (ru) 2010-12-30
CO6210700A2 (es) 2010-10-20
EP2222664A1 (en) 2010-09-01
NI201000086A (es) 2011-03-17
MX2010005488A (es) 2010-06-01
EP2222664B1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
NZ584998A (en) Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
NO341591B1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
PH12012500619A1 (en) 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
UA95949C2 (ru) Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
NZ595738A (en) Benzimidazole-piperidine-cyclohexane derivatives which have activity at M1 receptor and their uses in medicine
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DE602005015862D1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
MX2010009922A (es) Activadores de piridazinona glucocinasa.
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
ECSP077277A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
EP2004188A4 (en) BENZOIMIDAZOLE-2-YL PYRIDINES AS HISTAMINE H4 RECEPTOR MODULATORS
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE502006007587D1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
NO20081082L (no) Nye piperidinderivater som kjemokinreseptorformulatorer som er nyttige for behandling av respiratoriske sykdommer
TW200509920A (en) Imidazole derivatives
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2015 BY CPA GLOBAL

Effective date: 20130205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2018 BY CPA GLOBAL

Effective date: 20140903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2019 BY JAMES + WELLS

Effective date: 20181113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2020 BY IPAN GMBH

Effective date: 20191105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2021 BY CPA GLOBAL

Effective date: 20201015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2022 BY CPA GLOBAL

Effective date: 20210930

LAPS Patent lapsed